Drug-Coated Balloons for De Novo Coronary Artery Lesions: A Meta-Analysis of Randomized Clinical Trials

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2023 Sep 20

PMID 37727918

Authors

Dejin Wang

Xiqian Wang

Tianxiao Yang

Hongliang Tian

Yuanzhen Su

Qilei Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: Through meta-analysis, we aimed to assess the efficacy and safety of drug-coated balloons (DCB), compared with drug-eluting stents (DES) or uncoated devices, in the treatment of de novo coronary lesions.

Materials And Methods: Only randomized controlled trials were included. The primary outcomes were late lumen loss (LLL), target lesion revascularization (TLR), and major adverse cardiac events (MACEs). Subgroup analyses were conducted based on clinical indications, whether DCBs were used with a systematic or bailout stent, and types of DESs.

Results: The present meta-analysis demonstrated that DCBs elicit significantly lower incidences of TLR, MACE, and LLL, compared with uncoated devices, and similar incidences, compared with DESs, in the treatment of de novo coronary lesions. Subgroup analysis indicated that DCBs used with a bailout stent achieved lower incidences of binary restenosis and myocardial infarction, compared with uncoated devices, and provided less LLL than DESs. DCBs showed similar rates of TLR and MACE, with significantly less LLL, than DESs in treating de novo small-vessel diseases. The clinical efficacy of DCBs was similar to that of second-generation DES.

Conclusion: Overall, DCB is favored over bare metal stent alone in treating de novo coronary lesions. DCBs appear to be a promising alternative to DESs in the treatment of de novo coronary lesions.

Citing Articles

Safety and Performance of the MOZEC Sirolimus-Eluting Coronary Balloon in the Treatment of Stenotic Coronary Artery Lesions: A Real-World, Multicenter, Post-Marketing Surveillance Study.

Premchand Jain R, Parikh K, Sethuraman S, Sharma K, Roy S, Vithala S Cardiol Res. 2025; 16(2):130-139.

PMID: 40051667 PMC: 11882231. DOI: 10.14740/cr2026.

Drug coated balloon angioplasty for de novo coronary lesions in large vessels: a systematic review and meta-analysis.

Gobbi C, Giangiacomi F, Merinopoulos I, Gherbesi E, Faggiano A, Pasero G Sci Rep. 2025; 15(1):4921.

PMID: 39929903 PMC: 11811268. DOI: 10.1038/s41598-025-85734-4.

A Comparison of 2 Paclitaxel-Coated Balloon Systems in Treatment of De Novo Coronary Artery Lesions.

Fong A, Said A, Oon Y, Koh K, Ho K, Shu F J Soc Cardiovasc Angiogr Interv. 2024; 3(5):101295.

PMID: 39132464 PMC: 11308760. DOI: 10.1016/j.jscai.2024.101295.

References

Elgendy I, Gad M, Elgendy A, Mahmoud A, Mahmoud A, Cuesta J . Clinical and Angiographic Outcomes With Drug-Coated Balloons for De Novo Coronary Lesions: A Meta-Analysis of Randomized Clinical Trials. J Am Heart Assoc. 2020; 9(10):e016224. PMC: 7660863. DOI: 10.1161/JAHA.120.016224. View

Cortese B, Piraino D, Buccheri D, Alfonso F . Treatment of bifurcation lesions with drug-coated balloons: A review of currently available scientific data. Int J Cardiol. 2016; 220:589-94. DOI: 10.1016/j.ijcard.2016.06.079. View

Megaly M, Buda K, Saad M, Tawadros M, Elbadawi A, Basir M . Outcomes With Drug-Coated Balloons vs. Drug-Eluting Stents in Small-Vessel Coronary Artery Disease. Cardiovasc Revasc Med. 2021; 35:76-82. DOI: 10.1016/j.carrev.2021.03.008. View

Belkacemi A, Agostoni P, Nathoe H, Voskuil M, Shao C, Van Belle E . First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in.... J Am Coll Cardiol. 2012; 59(25):2327-37. DOI: 10.1016/j.jacc.2012.02.027. View

Byrne R, Neumann F, Mehilli J, Pinieck S, Wolff B, Tiroch K . Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2012; 381(9865):461-7. DOI: 10.1016/S0140-6736(12)61964-3. View

Joner M, Finn A, Farb A, Mont E, Kolodgie F, Ladich E . Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48(1):193-202. DOI: 10.1016/j.jacc.2006.03.042. View

Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits P . Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015; 65(23):2496-507. DOI: 10.1016/j.jacc.2015.04.017. View

Waksman R, Serra A, Loh J, Malik F, Torguson R, Stahnke S . Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. EuroIntervention. 2013; 9(5):613-9. DOI: 10.4244/EIJV9I5A98. View

Cassese S, Byrne R, Ndrepepa G, Kufner S, Wiebe J, Repp J . Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2015; 387(10018):537-544. DOI: 10.1016/S0140-6736(15)00979-4. View

10.

Cortese B, Bertoletti A . Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol. 2011; 161(1):4-12. DOI: 10.1016/j.ijcard.2011.08.855. View

11.

Lopez Minguez J, Asensio J, Doncel Vecino L, Sandoval J, Romany S, Martinez Romero P . A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results. EuroIntervention. 2014; 10(1):50-7. DOI: 10.4244/EIJV10I1A10. View

12.

Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C . Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. EuroIntervention. 2014; 11(8):926-34. DOI: 10.4244/EIJY14M08_12. View

13.

Alfonso F, Scheller B . State of the art: balloon catheter technologies - drug-coated balloon. EuroIntervention. 2017; 13(6):680-695. DOI: 10.4244/EIJ-D-17-00494. View

14.

Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell J, Sakakura K . Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2013; 129(2):211-23. PMC: 3915802. DOI: 10.1161/CIRCULATIONAHA.113.001790. View

15.

Kheiri B, Bachuwa G, Bhatt D . Drug-eluting stents versus bare-metal stents with a single month of dual antiplatelet therapy: a trial sequential analysis. J Thromb Thrombolysis. 2019; 48(1):11-13. DOI: 10.1007/s11239-019-01861-6. View

16.

Cortese B, di Palma G, Garcia Guimaraes M, Piraino D, Orrego P, Buccheri D . Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: PICCOLETO II Randomized Clinical Trial. JACC Cardiovasc Interv. 2020; 13(24):2840-2849. DOI: 10.1016/j.jcin.2020.08.035. View

17.

Schulz A, Hauschild T, Kleber F . Treatment of coronary de novo bifurcation lesions with DCB only strategy. Clin Res Cardiol. 2014; 103(6):451-6. DOI: 10.1007/s00392-014-0671-9. View

18.

Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F . A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol. 2012; 60(24):2473-80. DOI: 10.1016/j.jacc.2012.09.020. View

19.

Machecourt J, Danchin N, Lablanche J, Fauvel J, Bonnet J, Marliere S . Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007; 50(6):501-8. DOI: 10.1016/j.jacc.2007.04.051. View

20.

Jing Q, Zhao X, Han Y, Gao L, Zheng Y, Li Z . A drug-eluting Balloon for the trEatment of coronarY bifurcatiON lesions in the side branch: a prospective multicenter ranDomized (BEYOND) clinical trial in China. Chin Med J (Engl). 2020; 133(8):899-908. PMC: 7176447. DOI: 10.1097/CM9.0000000000000743. View